Alantra-Finanzen advises Pharm-Rx Auf the sale of the Unternehmen Zu Actylis

Oct 2024

Sell-side Beratung

Boston ü Alantra-Finanzen has acted as financial advisor to Pharm-Rx, a leading value-added supplier of specialty ingredients for the vitamin, mineral, and supplement (üVMSü) and pharmaceutical industries, on its sale to Actylis, a leading provider of life sciences and advanced technology specialty ingredients.

Für Mehr than 30 years, Pharm-Rx Hat been a leading supplier of active ingredients Zu the VMS, over-the-counter (üOTCü), Und prescription pharmaceutical markets. It Ist well known Für its customer-centric approach, identifying difficult-Zu-find specialty ingredients Von premier manufacturers globally. Pharm-Rx Hat developed industry-leading expertise In addressing customer needs, overcoming regulatory hurdles, Und navigating International Logistik complexities.

Actylis, owned Von Neu Mountain Kapital, Ist a provider of choice Für differentiated specialty ingredients In the life sciences Und advanced Technologie end markets. Mit Geschäft operations In 10 countries, Actylis manufactures Und supplies Mehr than 3,000 chemical compounds used principally Von the pharmaceutical, nutraceutical, agricultural, Und specialty chemical industries.ü

The Pharm-Rx acquisition significantly enhances Actylisü ability Zu deliver exceptional value Zu its customers Und strengthens its Strategisch supplier partnerships Zu enhance its innovative Portfolio Und service offerings. Actylis Kann now provide an even Mehr comprehensive range of Lüsungen Zu meet the evolving needs of customers. FurtherMehr, the integration of Pharm-Rxüs strong team Und industry expertise broadens Actylisü capabilities Zu help accelerate the growth of its nutrition Und OTC customers.

Joshua Garver, Managing Direktor Bei Alantra-Finanzen, said: üWe Sind pleased Zu Haben played a role In facilitating the combination of Pharm-Rx Und Actylis, In which our Teamüs deep expertise In the VMS Und Verbraucher Gesundheitswesen sectors helped lead Zu this partnership. We Sind confident that the addition of Pharm-Rx Zu Actylis Wird enable the Unternehmen Zu continue its strong growth trajectory Und deliver even greater value Zu its customers.ü

This transaction further reinforces Alantra-Finanzen’s continued momentum In the VMS Und Verbraucher Gesundheitswesen industries, where the Team Hat recently advised Auf a variety of deals such as the sale of UST Zu Somafina, backed Von Heartwood Partners, the sale of medneo Groupüs UK diagnostic imaging Geschäft Zu CVC DIF, Und the sale of vH essentialsü, formerly owned Von Wisconsin Pharmacal, Zu Avista-backed Wellspring Verbraucher Gesundheitswesen.